Changing pathology with changing drugs: Tumors of the gastrointestinal tract

Pathobiology

Volumn 78, Issue 2, 2011, Pages 76-89

  Cervera, Pascale ^a   Fléjou, Jean François ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Colon cancer; Gastrointestinal cancer; Molecular pathology; Targeted therapy

Indexed keywords

ALG 102; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; FORETINIB; GEMCITABINE; IMATINIB; IMITANIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OA 5D5; PANITUMUMAB; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TIVANTINIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; ONCOGENE C KIT; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; STOMACH SURGERY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PATHOLOGY, MOLECULAR; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79959313276     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000315535     Document Type: Review

References (108)

1. Dy GK, Adjei AA: Systemic cancer therapy: evolution over the last 60 years. Cancer 2008;113(suppl 7):1857-1887.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
4. Adjei AA, Hidalgo M: Treating cancer by blocking cell signals. J Clin Oncol 2005; 10; 23: 5279-5280. (Pubitemid 46206981)
5. Iannello A, Ahmad A: Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487-499. (Pubitemid 43096997)
6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 22; 351: 337-345. (Pubitemid 38944402)
7. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
8. Shepherd FA: A targeted approach to reducing lung cancer mortality. J Clin Oncol 2005; 23: 3173-3174.
9. Hurwitz H: Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004; 4(suppl 2):S62-S68.
10. Hamilton SR: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol 2008; 21(suppl 2):S23-S30.
11. Bralet MP, Paule B, Falissard B, Adam R, Guettier C: Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas. Histopathology 2007; 50: 210-216. (Pubitemid 46046389)
12. Messick CA, Sanchez J, Dejulius KL, Church JM, Kalady MF: Genetic and molecular diversity of colon cancer hepatic metastases. Surgery 2009; 146: 227-231.
13. Van Krieken JHJM, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 453: 417-431.
14. Tibiletti PG: Interphase FISH as a new tool in tumor pathology. Cytogenet Genome Res 2007; 118: 229-236.
15. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
16. You WK, McDonald DM: The hepatocyte growth factor/c-Met signalling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008; 41: 833-839.
17. Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem 1990; 265: 7709-7712. (Pubitemid 20158927)
18. Harding J, Burtness B: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005; 41: 107-127. (Pubitemid 40461533)
19. Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A: IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 2009; 40: 1528-1533.
20. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137. (Pubitemid 33674041)
21. Zhong L, Guo XN, Zhang XH, Sun QM, Tong LJ, Wu ZX, Luo XM, Jiang HL, Nan FJ, Zhang XW, Lin LP, Ding J: TKI-31 inhibits angiogenesis by combined suppression signalling pathway of VEGFR2 and PDGFRbeta. Cancer Biol Ther 2006; 5: 323-330.
22. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
23. Maynard MA, Ohh M: The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007; 64: 2170-2180. (Pubitemid 350103108)
24. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC: Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4- acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003; 88: 1160-1167.
25. Ma WW, Adjei, AA: Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009; 59: 111-137.
26. Kushner DM, Silverman RH: Antisense cancer therapy: the state of the science. Curr Oncol Rep 2000; 2: 23-30.
27. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915. (Pubitemid 39273730)
28. Sawyer TK: Novel oncogenic protein kinase inhibitors for cancer therapy. Curr Med Chem Anticancer Agents 2004; 4: 449-455.
29. Iannello A, Ahmad A: Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487-499. (Pubitemid 43096997)
30. Gewirtz AM: On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest 2007; 117: 3612-3614.
31. Weiner GJ: Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007; 39: 271-278.
32. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
33. Caron C, Boyault C, Khochbin S: Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 2005; 27: 408-415. (Pubitemid 40592597)
34. Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D: The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 2007; 31: 633-641.
35. Kim MS, Louwagie J, Carvalho B, Terhaar Sive Droste JS, Park HL, Chae YK, Yamashita K, Liu J, Ostrow KL, Ling S, Guerrero-Preston R, Demokan S, Yalniz Z, Dalay N, Meijer GA, Van Criekinge W, Sidransky D: Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One 2009; 4:e6555.
36. Haddad R, Ogilvie RT, Croitoru M, Muniz V, Gryfe R, Pollet A, Shanmugathasan P, Fitzgerald T, Law CH, Hanna SS, Jothy S, Redston M, Gallinger S, Smith AJ: Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol 2004; 11: 977-982. (Pubitemid 40486663)
37. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ, National Cancer Institute: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767-772. (Pubitemid 350002875)
38. Sinicrope FA, Sargent DJ: Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009; 21: 369-373.
39. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF: Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer: a systematic review and meta-analysis. Anticancer Res 2009; 29: 1615-1620.
40. Warusavitarne J, Schnitzler M: The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 2007; 22: 739-748. (Pubitemid 46863751)
41. Grávalos C, García-Escobar I, García-Alfonso P, Cassinello J, Malón D, Carrato A: Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin Transl Oncol 2009; 11: 526-533.
42. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2009; 772-780.
43. Mendelsohn J, Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369-385. (Pubitemid 44142736)
44. Cartenì G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C: Panitumumab a novel drug in cancer treatment. Ann Oncol 2007; 18(suppl 6):vi16-vi21.
45. Harari PM, Allen GW, Bonner JA: Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25: 4057-4065. (Pubitemid 47492950)
46. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810. (Pubitemid 46211358)
47. Lièvre A, Laurent-Puig P: Molecular biology in clinical cancer research: the example of digestive cancers (in French). Rev Epidemiol Sante Publique 2005; 53: 267-282. (Pubitemid 41044381)
48. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286. (Pubitemid 40590264)
49. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245. (Pubitemid 47325607)
50. Lièvre A, Laurent-Puig P: Predictive factors of response to anti-EGFR treatments in colorectal cancer (in French). Bull Cancer 2008; 95: 133-140. (Pubitemid 351262492)
51. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-515. (Pubitemid 351325672)
52. Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19: 717-723. (Pubitemid 351461042)
53. Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D, Daidone MG, Pilotti S, Pierotti MA, Bardelli A: PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 2008; 29: 284-288. (Pubitemid 351240601)
54. Hamada K, Monnai M, Kawai K, Nishime C, Kito C, Miyazaki N, Ohnishi Y, Nakamura M, Suemizu H: Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice. Int J Oncol 2008; 32: 153-159. (Pubitemid 351176073)
55. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934. (Pubitemid 34976022)
56. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145. (Pubitemid 47587019)
57. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bache J-B, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930.
58. Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, Oliveira C, Seruca R: BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis. BMC Cancer 2008;8: 255.
59. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68: 8541-8546.
60. Kawaguchi M, Yanokura M, Banno K, Kobayashi Y, Kuwabara Y, Kobayashi M, Nomura H, Hirasawa A, Susumu N, Aoki D: Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int J Oncol 2009; 34: 1541-1547.
61. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL: Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28: 3801-3813.
62. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, Sabourin J-C, Boissiere-Michot F: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with Cetuximab plus Irinotecan. J Clin Oncol 2009; 27: 1122-1129.
63. Folkman J, Merler E, Abernathy C, Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
64. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-3968.
65. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544. (Pubitemid 46733080)
66. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003: 677-684. (Pubitemid 36749216)
67. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139. (Pubitemid 16169997)
68. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G: The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 2009; 34: 641-651.
69. Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
70. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52: 797-805. (Pubitemid 351724903)
71. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard M-P, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Keipe HH: Her2 diagnostics in gastric cancer - guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
72. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009: 27: 18s.
73. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19: 4947-4953.
74. Park WS, Oh RR, Kim YS, Park JY, Shin MS, Lee HK, Lee SH, Yoo NJ, Lee JY: Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. APMIS 2000; 108: 195-200. (Pubitemid 30158999)
75. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925. (Pubitemid 37493640)
76. Rosário M, Birchmeier W: How to make tubes: signalling by the Met receptor tyrosine kinase. Trends Cell Biol 2003; 13: 328-335. (Pubitemid 36638800)
77. Yu J, Miehlke S, Ebert MP, Hoffmann J, Breidert M, Alpen B, Starzynska T, Stolte M, Malfertheiner P, Bayerdörffer E: Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer 2000; 88: 1801-1806. (Pubitemid 30212988)
78. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F, EUROCARE Working Group: Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007; 102: 1661-1670. (Pubitemid 47206702)
79. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008: 48: 1312-1327.
80. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008: 359: 378-390.
81. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM: Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68: 6779-6788.
82. Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM: Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009: 25: 186-194.
83. Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH: Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg 2009; 13: 1510-1516.
84. Rocha-Lima CM: New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs 2008; 19: 435-446.
85. Benson AB, Moore M: Accomplishments in 2007 in the management of localized pancreatic cancer. Gastrointest Cancer Res 2008; 2(3 suppl):S32-S36.
86. Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M: Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene 2009; 28: 610-618.
87. Cichoz-Lach H, Kasztelan-Szczerbińska B, Słomka M: Gastrointestinal stromal tumors: epidemiology, clinical picture, diagnosis, prognosis and treatment. Pol Arch Med Wewn 2008; 118: 216-221. (Pubitemid 351613062)
88. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58. (Pubitemid 30043939)
89. Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, Hoekstra HJ, van den Berg E, Scheper RJ, van der Graaf WT: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-3220.
90. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580. (Pubitemid 28067289)
91. Miettinen M, Wang ZF, Lasota J: DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1,840 cases. Am J Surg Pathol 2009; 33: 1401-1408.
92. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53-60. (Pubitemid 29031611)
93. Tazawa K, Tsukada K, Makuuchi H, Tsutsumi Y: An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol Int 1999; 49: 786-798. (Pubitemid 29513293)
94. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932. (Pubitemid 30618049)
95. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054-5058. (Pubitemid 32769795)
96. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056. (Pubitemid 32267975)
97. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-667. (Pubitemid 37070684)
98. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710. (Pubitemid 36159485)
99. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364. (Pubitemid 46206989)
100. Rink L, Skorobogatko Y, Kossenkov AV, Belinsky MG, Pajak T, Heinrich MC, Blanke CD, von Mehren M, Ochs MF, Eisenberg B, Godwin AK: Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther 2009; 8: 2172-2182.
101. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-4774. (Pubitemid 46630941)
102. Blay JY: Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol 2010; 21: 208-215.
103. Heinrich MC, Corless CL: Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol 2005; 90: 195-207. (Pubitemid 40741187)
104. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD, GIST consensus meeting panellists. Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-578. (Pubitemid 40613322)
105. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG: Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009: 15: 5902-5909.
106. Druker BJ: Overcoming resistance to imatinib by combining targeted agents. Mol Cancer Ther 2003; 2: 225-226.
107. Fletcher JA, Rubin BP: KIT mutations in GIST. Curr Opin Genet Dev 2007; 17: 3-7. (Pubitemid 46109300)
108. Bonvalot S, Eldweny H, Péchoux CL, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N, Cesne AL: Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13: 1596-1603. (Pubitemid 44951467)